Skip to content
Screener

Crinetics Pharmaceuticals CRNX Business Segments — Selling, General and Administrative Expense

Similar metrics at other companies

Lowe's Companies logo
LOWReportable Segment — Selling, General and Administrative Expense
$4.19B+3.6%
Moog Inc. logo
MOG.AReportable segments — Selling, General and Administrative Expense
$125.92M+11.1%
Ralph Lauren logo
RLOther non-reportable segments — Selling, General and Administrative Expense
$4.1M+7.9%
Signet Jewelers logo
SIGInternational segment — Selling, General and Administrative Expense
$29.9M+13.7%
Wabtec logo
WABFreight Segment — Selling, General and Administrative Expense
$219M+21.0%
Wabtec logo
WABTransit Segment — Selling, General and Administrative Expense
$131M+14.9%

Other financials

Income statement

See full
Revenue$10.7M+2,873%
Gross profit$10.5M+2,818%
Operating income-$140.4M-26.0%
Net income-$127.8M-32.1%
EPS (diluted)-$1.23-18.3%

Balance sheet

See full
Cash & equivalents$115.1M+20.1%
Total debt$47.9M-5.8%
Total equity$1.3B+2.1%
Total assets$1.4B+2.9%

Cash flow

See full
Operating cash flow-$124.7M-41.0%
CapEx$820.0K-33.8%
Free cash flow-$125.5M-40.0%

Valuation

See full
Market cap$8.9B+233%
Enterprise value$8.84B+231%
P/S492.8×-1,427×

Profitability

See full
Gross margin150%-15.6pp
Operating margin-3,020.3%-1,463pp
Net margin-2,747.2%-1,328pp
FCF margin-2,321.7%-1,122pp

Returns & leverage

See full
Return on equity-39.2%+14.5pp
Debt / equity0.0×
Current ratio18.6×-3.9×

Where this comes from

Reported directly by Crinetics Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The source filing: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:21 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001658247-26-000040
Line itemThree months ended March 31, 2026Three months ended March 31, 2025
Total research and development expenses(100,081)(76,240)
Selling, general and administrative
Other selling, general and administrative expenses (2)(20,442)(14,774)
Selling, general and administrative personnel expenses(20,037)(12,093)
Selling, general and administrative stock-based compensation(10,352)(8,659)
Total selling, general and administrative expenses(50,831)(35,526)
Total other income, net12,53314,631
Segment and consolidated net loss$(127,845)$(96,774)

Item 1. Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is Crinetics Pharmaceuticals's business segments — selling, general and administrative expense?
Crinetics Pharmaceuticals (CRNX) reported business segments — selling, general and administrative expense of $50.83M in Q1 2026.
How has Crinetics Pharmaceuticals's business segments — selling, general and administrative expense changed year-over-year?
Crinetics Pharmaceuticals's business segments — selling, general and administrative expense increased by 43.1% year-over-year, from $35.53M to $50.83M.
What does business segments — selling, general and administrative expense mean?
Captures the aggregate costs associated with operating the business, including administrative overhead, legal, marketing, and commercial support functions. This metric reflects the company's overall operational scale and the resources allocated to support corporate infrastructure and product commercialization. Monitoring this helps evaluate the company's ability to manage fixed costs while scaling operations.

Ask your AI about Crinetics Pharmaceuticals's business segments — selling, general and administrative expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude